EPO fees from April 2026: update the budget, not just the payment table

horak Rechtsanwälte · Patent insights and case law

English · Deutsch · Français

Published and reviewed: 17 November 2026. Event date: 1 April 2026, when the revised fee arrangements took effect. This article examines practical consequences for patent applicants and proprietors; it is not a quotation for a particular filing.

The spring fee revision matters wherever a European patent budget was prepared using an older schedule. An application budget is often approved months before the relevant payment. Procurement may hold a fixed estimate while the patent team is working with an updated timetable. The useful response is a reconciliation of the pending actions, applicable fees and payment instructions, rather than a general percentage increase applied to every item.

What changed and what must be distinguished

Decision CA/D 9/25 revised the EPO fee schedule, generally for payments made from 1 April 2026, with specific transitional provisions. Its schedule includes a EUR 1,595 European search fee and a EUR 1,135 grant fee. A separate presidential decision revised administrative fees and expenses. These are distinct instruments and should be read together. [1] [2]

Unitary Patent renewal fees have their own schedule. The EPO’s current cost comparison identifies national renewal-fee figures as of April 2026; that update should not be described as proof that every Unitary Patent renewal fee increased. Compare like-for-like rights and patent years before drawing a cost conclusion. [3]

Turn the change into a controlled workflow

Create a list of payments expected in the next six months, identifying the application number, procedural act, fee code, due date and responsible payer. Separate official fees from professional fees, translations and technical work. Confirm whether a quotation assumed a particular filing route or number of claims. An apparently small discrepancy can indicate that the wrong procedural stage, rather than merely an old amount, has been selected.

For payments already made, preserve the debit confirmation and reconcile it with the file. If a shortfall is suspected, assess the relevant provision and any communication from the EPO promptly. The historical transitional mechanism should not be treated as an unlimited permission to underpay. In particular, a budget adjustment does not extend a procedural deadline or replace the required act.

Four practical examples

The following are hypothetical working examples, not descriptions of client matters or predictions of an official decision.

1. An old purchase order remains active

A manufacturer approves a filing estimate early in the year but releases payment after the revision. The patent team checks the current fee and updates the internal purchase order. It also records which external costs remain unchanged, avoiding a misleading blanket surcharge on the entire instruction.

2. A European-phase entry is mispriced

A finance team uses a direct-European filing template for an international application entering the European phase. Counsel checks the applicable search and examination position before authorising payment. Correcting the route assumptions is more important than simply replacing the date on the estimate.

3. Several patent years are confused

A portfolio report compares an application renewal with a granted Unitary Patent renewal. The figures appear inconsistent because they concern different rights and stages. The team separates the fee categories and uses the relevant patent year, producing a budget the business can actually compare.

4. A payment confirmation is missing

The business believes an agent has paid, while the agent is waiting for approval. A shared responsibility record identifies the gap before the deadline. The team obtains evidence of completed payment rather than treating an invoice or an internal approval as equivalent to payment.

The business decision

Keep a versioned fee schedule, a clear approval limit and an escalation contact for urgent discrepancies. For a portfolio review, model the remaining life of each commercially relevant asset. The objective is reliable protection within an understood budget, with a documented reason for each filing, renewal or abandonment decision.

Official sources

[1] OJ 2026, A2: fee schedule · [2] OJ 2026, A3: administrative fees · [3] Unitary Patent costs

Discuss the filing, deadline and commercial objective with our patent team. Please withhold confidential technical details until the conflict check is complete.

Contact the patent team